Drugs / Filgrastim-SD/01
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00004853 | Mar 2000 → May 2009 | Ewing sarcoma, malignant peripheral nerve sheath tumor, rhabdomyosarcoma, synovial sarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Filgrastim-SD/01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004853 ↗ |
| Modality | Protein / enzyme biologic | “Filgrastim-SD/01 (AMGEN), which is produced by PEGylation of the amino-terminus of filgrastim, is a sustained duration form of granulocyte colony-stimulating factor.” NCT00004853 ↗ |
| Route | Subcutaneous | “100 microgram/kg SC 24-36 hours after last dose of chemotherapy (single dose)” NCT00004853 ↗ |